The ability of Herceptin® to prolong survival in women with HER2-overexpressing breast
tumors has proven the concept of using humanized or chimeric monoclonal antibodies …

The invention relates to novel bispecific antibodies and their use in tumor therapy. The novel
antibodies have the ability to bind to ErbB receptors, preferably ErbB1 receptors, which are …

The recognition that few human diseases are thoroughly addressed by mono-specific,
monoclonal antibodies (mAbs) continues to drive the development of antibody therapeutics …

Monoclonal antibody-based targeted tumor therapy has greatly improved treatment options
for patients. Antibodies against oncogenic receptor tyrosine kinases (RTKs), especially the …

Background One-third of breast cancers display amplifications of the ERBB2 gene encoding
the HER2 kinase receptor. Trastuzumab, a humanized antibody directed against an epitope …

The human epidermal growth factor receptor (HER) family consists of four transmembrane
receptor tyrosine kinases: epidermal growth factor receptor (EGFR), HER2, HER3, and …

A new human, compact antibody was engineered by fusion of a human, antitumour ErbB2-
directed scFv with a human IgG1 Fc domain. Overexpression of the ErbB2 receptor is related …

Highlights•HER3 is a tyrosine kinase receptor belonging to the HER family, ubiquitously
expressed across different solid tumors.•HER3 has a role in tumorigenesis, disease …

HER2/HER3 dimerization resulting from overexpression of HER2 or neuregulin (NRG1) in
cancer leads to HER3-mediated oncogenic activation of phosphoinositide 3-kinase (PI3K) …

To facilitate comparative oncology trials we compared the biological and molecular
homologies of canine (dog; Canis lupus familiaris) and human tumor-associated antigens …